Biopharma Quarterly Dealmaking Statistics, Q3 2018
A look at financing, M&A and alliance activity July-September 2018
Biopharma financing reached $14.6 billion in the third quarter, a 15% increase over Q2, while merger and acquisitions, at $7.7 billion (the lowest quarter of the year so far), showed a sharp decline. Alliance value reached $20.3 billion, far exceeding the $13.8 billion from Q2.
You may also be interested in...
Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics. Roche sees combo future for Tusk’s cancer immunotherapy with its own portfolio. Total deal value could reach €655m.
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
Novartis's proposed sale of its generic oral solids portfolio – which has been battered by US price erosion – and the Sandoz US dermatology business to Aurobindo Pharma, in a deal potentially worth $1bn, allows the unit to finally concentrate on biosimilars, value-added medicines and complex generics.